Vontobel Holding Ltd. Takes $68,000 Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Vontobel Holding Ltd. acquired a new stake in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) during the third quarter, HoldingsChannel.com reports. The institutional investor acquired 15,723 shares of the company’s stock, valued at approximately $68,000.

Other institutional investors have also added to or reduced their stakes in the company. Susquehanna Fundamental Investments LLC bought a new stake in shares of Black Diamond Therapeutics during the first quarter valued at about $82,000. SG Americas Securities LLC purchased a new position in Black Diamond Therapeutics during the second quarter valued at approximately $108,000. Algert Global LLC bought a new stake in Black Diamond Therapeutics during the 2nd quarter worth approximately $133,000. Rhumbline Advisers lifted its stake in Black Diamond Therapeutics by 10,334.3% in the 2nd quarter. Rhumbline Advisers now owns 46,850 shares of the company’s stock worth $218,000 after purchasing an additional 46,401 shares in the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new stake in Black Diamond Therapeutics in the 2nd quarter worth approximately $280,000. Hedge funds and other institutional investors own 95.47% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Piper Sandler upped their price target on shares of Black Diamond Therapeutics from $12.00 to $15.00 and gave the stock an “overweight” rating in a report on Monday, September 23rd. Wedbush restated an “outperform” rating and issued a $16.00 target price on shares of Black Diamond Therapeutics in a research note on Tuesday, October 8th. Raymond James started coverage on Black Diamond Therapeutics in a report on Wednesday, July 31st. They issued an “outperform” rating and a $20.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Black Diamond Therapeutics in a research report on Wednesday, October 9th.

Black Diamond Therapeutics Stock Performance

Shares of NASDAQ:BDTX opened at $3.06 on Thursday. The firm has a market capitalization of $172.13 million, a PE ratio of -1.84 and a beta of 2.47. Black Diamond Therapeutics, Inc. has a 52-week low of $1.62 and a 52-week high of $7.66. The firm has a fifty day moving average of $4.82 and a 200 day moving average of $5.19.

Black Diamond Therapeutics (NASDAQ:BDTX) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. On average, sell-side analysts forecast that Black Diamond Therapeutics, Inc. will post -1.44 EPS for the current fiscal year.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.